Rate this post

Holsworth to lead clinical analysis efforts and solution improvement of new CBD options

HENDERSON, Nev. – MArch four, 2019 /Canna Newswire/ – Major Edge Pharms, Inc., (LEP) a biotechnology enterprise building novel cannabinoid therapies and revolutionary delivery systems, announced now that Dr. Daniel Holsworth has been appointed Chief Science Officer (CSO).

Dr. Holsworth’s appointment signals LEP’s additional commitment to giving clinically supported CBD-primarily based options for topical discomfort relief and inflammatory skin situations.

“One of our crucial differentiators has generally been a commitment to clinical thoroughness, even as quite a few CBD goods are getting rushed to market place to capitalize on a new trend,” mentioned David Chadwick, CEO of LEP. “Dan has been an crucial element of the LEP group for two years as a consultant and was instrumental in the improvement of Silvidiol™, our liposomal CBD compound and delivery method. Now, as CSO, Dan will lead our analysis and improvement efforts and be straight accountable for the formulation of quite a few thrilling new goods LEP will be releasing in 2019. We appear forward to functioning closely collectively to advance the scientific operate getting accomplished inside the cannabis sector.”

Dr. Holsworth joins the enterprise with 25 years of knowledge as a drug discovery and improvement specialist, entrepreneur and regulatory affairs qualified.  He has comprehensive knowledge in treating inflammatory skin situations. For the duration of his tenure with CA Botana International, Dr. Holsworth formulated therapeutic skin care goods employing stem cell improvement pathway biology and peptide chemistry. He holds 25 patents for his discoveries.

“Pharmaceuticals addressing discomfort typically have unfortunate side effects and can even be addictive. On top of that, these drugs unnecessarily effect the complete physique, rather than targeting particular discomfort web sites. CBD is a organic discomfort reliever and can be employed properly to target peripheral neuropathic discomfort at the nerve level exactly where discomfort happens,” explained Dr. Holsworth. “Our vision at LEP is to bring CBD therapies into mainstream clinical practice as a initially step in discomfort management. There are other organic and successful options out there, and sufferers really should be conscious of their selections.”

Previously, Dr. Holsworth was an Associate Investigation Fellow medicinal chemist at Pfizer, Co-Founder and Head of Chemistry at ODIN Therapeutics AS and Technical Advisor for CA Botana International.

Major Edge Pharms, Inc. (LEP) is a biotechnology enterprise focused on the analysis, improvement and commercialization of novel cannabinoid therapies and revolutionary delivery platforms. LEP is the developer of CANNAVERA™ discomfort relief goods, out there in pharmacies across the United States. All LEP goods are manufactured in FDA registered facilities adhering to present Excellent Manufacturing Practices and are out there at www.LENCURA.com. Discover far more at www.leadingedge.com.

# CNW #

Major Edge Pharms Enterprise Make contact with:
David Chadwick, CEO
[email protected]
(800) 813-0013

Major Edge Pharms Media Make contact with:
Nicole Grubner
[email protected]
(929) 222-8011